Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid ...

Novo Nordisk has ousted chief executive Lars Fruergaard Jørgensen as the maker of pioneering obesity drug Ozempic battles a slump in profit growth, declining market share and a plunging stock price.

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

If you make a purchase via links on this page we will earn commission - learn more Ozempic and Wegovy are household names that have revolutionized the weight loss industry — a market already ...

Similar to other Ozempic-like drugs, the pill is part of the GLP-1 receptor family, which help regulate blood sugar and appetite. There is a GLP-1 pill on the market now called Rybelsus, however it ...

A look inside the rise of "The Barbie Drug," an unregulated, understudied injection that promises bronzed skin—and a load of ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will step down after eight years at the helm, as the Danish pharmaceutical giant ...

Brigham Buhler, a MAHA influencer and biotech entrepreneur, has Robert F. Kennedy’s ear. But will RFK listen to his call to ...

"The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor explains options for patients.